Nature - USA (2020-09-24)

Article

a

25μm

PTS1-GFP

Hoechst 33342

-2 -1 0

0.0

0.4

0.8

1.2

Relative

viabilit

y

-2 -1 0

0.0

0.4

0.8

1.2

Log10(M ML210)

Relative

viabilit

y

-3 -2 -1

AGPS-sg2

AGPS-sg1

sgNC

-3 -2 -1

Log 10 (μM RSL3)

sgNC

FAR1-sg1

-2 -1 0

0.0

0.4

0.8

1.2

Relative

viabilit

y

-3 -2 -1

PEX12-sg2

sgNC

PEX12-sg1

FAR1-sg1

AGPS-sg1 AGPS-sg2

PEX12-sg1 PEX12-sg2

-3 -2 -1 0

0.0

0.4

0.8

1.2

Relative

viability

0.0

0.4

0.8

1.2

-3 -2 -1 0

-3 -2 -1 0

PEX3-sg2

sgNC

PEX3-sg1

PEX10-sg 2

sgNC

PEX10-sg1

PEX10-sg1 PEX10-sg2

PEX3-sg1 PEX3-sg2

HuH7-sgNC

b

c

d

-2 -1 0

0.0

0.4

0.8

1.2

-2 -1 0

0.0

0.4

0.8

1.2

-3 -2 -1 0

-3 -2 -1 0

HuH-7:

SNU-685:

sgNC

FAR1-sg 1

AGPS-sg2

AGPS-sg1

sgNC

Log10(M ML210) Log 10 (μM RSL3)

Relativev

iabilit

y

Relativev

iabilit

y

e

β-Actin

AGPS

sgNC sg1 sg2

HuH-7 cells

sgNC

PEX3-sg1PEX3-sg2PEX10-sg1PEX10-sg2PEX12-sg1PEX12-sg2AGPS-sg1AGPS-sg2FA

R1-sg1

0

50

100

500

1000

1500

#P

uncta

in

eac

hc

ell

HuH-7

-3 -2 -1

0.0

0.5

1.0

1.5

Relativ

ev

iabilit

y

-3.0 -1.5 0. 01 .5 3. 0

0

5

10

15

Log 2 (ccRCC/normal)

other phospholipids

Ether-phospholipids

Total phospholipids

-4 -2 02

10

20

30

Log 2 (ccRCC/normal)

diacyl-PE

ePE

• Log

10

padj.

C40:6 ePE

C40:5 ePE

C38:6 ePC40:7 ePEE

C36:4 PE

C36:5 PEC38:6 PE

PE & ePE

-1 012

0

5

10

15

Log 2 (ccRCC/normal)

diacyl-PePC C

C38:5 ePC

C32:1 ePC

C36:5 ePC

C34:3 ePC

C36:5 PC

C34:1 PC

C38:6 PC

C36:4 PC

PC & ePC

f

0

Extended Data Fig. 6 | See next page for caption.